SIXTH AMENDMENT TO COLLABORATION AGREEMENT
Exhibit 10.27
***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under
17 C.F.R. Sections 200.80(b)(4) and 240.24b-2
SIXTH AMENDMENT TO
This Sixth Amendment (“Sixth Amendment”) to the Collaboration Agreement (the “Agreement”) by and between X. Xxxxxxxx-Xx Xxxxx Ltd, with an office and place of business at Xxxxxxxxxxxxxxxxx 000, 0000, Xxxxx, Xxxxxxxxxxx, and Xxxxxxxx-Xx Xxxxx Inc., with an office and place of business at 000 Xxxxx Xxxx, Xxxxx 0, Xxxxxx Xxxxx, Xxx Xxxxxx 00000, X.X.X. (together, “Roche”), on the one hand, and Foundation Medicine, Inc., with an office and place of business at 000 Xxxxxx Xxxxxx, Xxxxxxxxx, XX 00000, X.X.X. (“FMI”), on the other hand (each a “Party,” and collectively, the “Parties”), as such Agreement has been amended from time to time, is entered into by and between the Parties and shall be considered effective as of the 1st of November, 2017 (the “Sixth Amendment Effective Date”). Capitalized terms used in this Sixth Amendment and not otherwise defined herein are used with the meanings ascribed to them in the Agreement.
|
1. |
Section 1.27. Section 1.27 of the Agreement is hereby replaced with the following: |
“1.27 |
Excepted Activities |
The term “Excepted Activities” shall mean […***…].
[Signature page follows.]
***Confidential Treatment Requested***
IN WITNESS WHEREOF, the Parties hereto have caused this Sixth Amendment to be executed and effective as of the Sixth Amendment Effective Date. All other terms and conditions of the Agreement remain in force and effect.
X. XXXXXXXX-XX XXXXX LTD |
Signed: /s/ Xxxxxxx XxxxxxxxxxSigned: /s/ Xxxxxx Xxxxxx
Name: Xxxxxxx XxxxxxxxxxName: Xxxxxx Xxxxxx
Title: CBO and Head, BiopharmaTitle: Head Legal Pharma
|
X. XXXXXXXX-XX XXXXX LTD |
Signed: /s/ Xxxxx Xxxxxxxxxx
Name: Xxxxx Xxxxxxxxxx
Title: XXX
|
XXXXXXXX-XX XXXXX INC. |
Signed: /s/ Xxxx X. Xxxxxx
Name: Xxxx X. Xxxxxx
Title: Authorized Signatory
***Confidential Treatment Requested***
2